EA201590797A1 - Препараты с модифицированным высвобождением опрозомиба - Google Patents
Препараты с модифицированным высвобождением опрозомибаInfo
- Publication number
- EA201590797A1 EA201590797A1 EA201590797A EA201590797A EA201590797A1 EA 201590797 A1 EA201590797 A1 EA 201590797A1 EA 201590797 A EA201590797 A EA 201590797A EA 201590797 A EA201590797 A EA 201590797A EA 201590797 A1 EA201590797 A1 EA 201590797A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- preparations
- modified probe
- probe release
- pharmaceutical preparations
- release
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 239000000523 sample Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 108010064641 ONX 0912 Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 abstract 1
- 229950005750 oprozomib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/066679 WO2014066681A1 (en) | 2012-10-24 | 2013-10-24 | Modified release formulations for oprozomib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201590797A1 true EA201590797A1 (ru) | 2016-02-29 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590797A EA201590797A1 (ru) | 2012-10-24 | 2013-10-24 | Препараты с модифицированным высвобождением опрозомиба |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (enExample) |
| EP (1) | EP2912025A4 (enExample) |
| JP (1) | JP6505604B2 (enExample) |
| KR (1) | KR20150070406A (enExample) |
| CN (1) | CN104968650A (enExample) |
| AP (1) | AP3681A (enExample) |
| AR (1) | AR093126A1 (enExample) |
| AU (1) | AU2013334258A1 (enExample) |
| BR (1) | BR112015008572A2 (enExample) |
| CA (1) | CA2888039A1 (enExample) |
| CL (1) | CL2015001085A1 (enExample) |
| CR (1) | CR20150266A (enExample) |
| EA (1) | EA201590797A1 (enExample) |
| HK (2) | HK1208222A1 (enExample) |
| IL (1) | IL238244A0 (enExample) |
| IN (1) | IN2015DN03921A (enExample) |
| MX (1) | MX2015005069A (enExample) |
| PE (1) | PE20151051A1 (enExample) |
| PH (1) | PH12015500823A1 (enExample) |
| SG (1) | SG11201502849XA (enExample) |
| TN (1) | TN2015000135A1 (enExample) |
| TW (1) | TW201422255A (enExample) |
| UY (1) | UY35091A (enExample) |
| WO (1) | WO2014066681A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| WO2018005781A1 (en) | 2016-06-29 | 2018-01-04 | Kezar Life Sciences | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof |
| US20180078532A1 (en) * | 2016-09-21 | 2018-03-22 | Amgen Inc. | Immediate release formulations for oprozomib |
| WO2018112078A1 (en) | 2016-12-14 | 2018-06-21 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| BR112020005079A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| EA011451B1 (ru) * | 2001-02-12 | 2009-04-28 | Уайт | Новая соль сукцинат о-десметилвенлафаксина |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| EP2623113B1 (en) * | 2005-11-09 | 2017-05-31 | Onyx Therapeutics, Inc. | Compound for enzyme inhibition |
| US20100172988A1 (en) * | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CA2701778C (en) * | 2007-10-04 | 2018-09-11 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| AR075899A1 (es) * | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
-
2013
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en not_active Ceased
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2912025A4 (en) | 2016-06-08 |
| PH12015500823A1 (en) | 2015-06-22 |
| WO2014066681A1 (en) | 2014-05-01 |
| JP2015535255A (ja) | 2015-12-10 |
| TN2015000135A1 (en) | 2016-10-03 |
| US9295708B2 (en) | 2016-03-29 |
| PE20151051A1 (es) | 2015-08-03 |
| TW201422255A (zh) | 2014-06-16 |
| CN104968650A (zh) | 2015-10-07 |
| SG11201502849XA (en) | 2015-05-28 |
| BR112015008572A2 (pt) | 2017-07-04 |
| KR20150070406A (ko) | 2015-06-24 |
| EP2912025A1 (en) | 2015-09-02 |
| CA2888039A1 (en) | 2014-05-01 |
| AR093126A1 (es) | 2015-05-20 |
| JP6505604B2 (ja) | 2019-04-24 |
| AU2013334258A1 (en) | 2015-04-30 |
| CR20150266A (es) | 2015-08-14 |
| MX2015005069A (es) | 2015-07-17 |
| IN2015DN03921A (enExample) | 2015-10-02 |
| IL238244A0 (en) | 2015-06-30 |
| UY35091A (es) | 2014-05-30 |
| HK1215709A1 (zh) | 2016-09-09 |
| US20140113855A1 (en) | 2014-04-24 |
| US20160213610A1 (en) | 2016-07-28 |
| AP2015008387A0 (en) | 2015-04-30 |
| AP3681A (en) | 2016-04-19 |
| HK1208222A1 (en) | 2016-02-26 |
| CL2015001085A1 (es) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| CO6640206A2 (es) | Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo | |
| EA202090573A1 (ru) | Составы нирапариба | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| WO2011157416A3 (de) | Transdermale verabreichung von memantin | |
| EA201101706A1 (ru) | Лекарственное средство на основе дииндолилметана(dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека | |
| EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
| EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| EA201500112A1 (ru) | 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств | |
| MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| EA201691160A1 (ru) | Антагонисты s1p3 | |
| EA201691034A1 (ru) | Композиции в твердой форме с замедленным высвобождением для перорального введения | |
| EA201691231A1 (ru) | Фармацевтические лекарственные формы | |
| UA109544C2 (uk) | Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення | |
| IL217519A (en) | Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| EA201500232A1 (ru) | Три(гетеро)арилпиразолы и их применение | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib |